Viemed Healthcare, Inc.
6.54-0.32 (-4.66%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · VMD · USD
Key Stats
Market Cap
253.66MP/E (TTM)
19.24Basic EPS (TTM)
0.34Dividend Yield
0%Recent Filings
8-K
Record Q2 revenues, acquisition closed
Viemed Healthcare reported record Q2 2025 net revenues of $63.1 million, up 14.7% year-over-year, with net income surging 115% to $3.2 million amid robust patient growth in ventilators (up 11.4% to 12,152) and PAP therapy (up 51.4% to 26,260). Adjusted EBITDA rose 11.5% to $14.3 million, bolstered by favorable product mix and expense leverage. The company closed its $26 million acquisition of Lehan's Medical Equipment on July 1, prompting raised full-year guidance to $271–277 million in revenue and $59–62 million in Adjusted EBITDA. Integration challenges could temper synergies.
10-Q
Q2 FY2025 results
Viemed Healthcare posted solid Q2 results, with revenue climbing 14.7% year-over-year to $63.1 million, fueled by 11.1% growth in ventilator rentals to $33.8 million and 29.0% in equipment sales to $9.5 million, while gross margin dipped to 58.3% from 59.8% on a shifting revenue mix. Operating income jumped 40.9% to $5.1 million, and diluted EPS held at $0.08, aligning with 41.1 million weighted shares. Cash from operations hit $15.1 million year-to-date, up from $11.4 million, boosting cash to $20.0 million despite $23.6 million in capex; total debt stayed low at $4.3 million under the 2022 facilities maturing 2027, with full covenant compliance. The April 2024 HomeMed buy added $3.2 million goodwill, and July's $26 million Lehan's deal—funded by $18 million debt and cash—eyes geographic gains. Revenue relies heavily on Medicare, now 40% of total.
8-K
Viemed closes Lehan acquisition
Viemed Healthcare completed its acquisition of Illinois-based Lehan's Medical Equipment on July 2, 2025, for a base price of $26 million plus $2.2 million in estimated contingent payments, funded by cash and borrowings. Lehan, with 2024 net revenues of $25.7 million and Adjusted EBITDA of $7.4 million, bolsters Viemed's home medical equipment offerings in a fast-growing market. The deal integrates Lehan's regional expertise with Viemed's national scale. Viemed plans to update its 2025 guidance in Q2 earnings. Integration challenges loom large.
8-K
Viemed launches share buyback
Viemed Healthcare amended its credit agreement on June 6, 2025, to allow greater restricted payments, including share repurchases, while maintaining a leverage ratio below 2.0:1.0 and no defaults. The board then authorized buying back up to 1,976,441 common shares—about 5% of outstanding—through June 2026 via open market or block trades under Rule 10b-18. Backed by no net debt and full $55 million credit access, this signals confidence in growth. Repurchases hinge on market prices and liquidity.
8-K
LTIP amendment approved
Viemed Healthcare shareholders approved an amendment to the 2024 Long Term Incentive Plan at the June 5, 2025 annual meeting, boosting the share pool to 7,904,769 while mandating a one-year minimum vesting for most awards, except 5% carve-out. The change clarifies accelerated vesting on change in control, securing talent amid growth. Directors were unanimously re-elected. Strong say-on-pay support signals alignment.
AHCO
AdaptHealth Corp.
9.17-0.30
ELMD
Electromed, Inc.
24.01-0.43
IRMD
iRadimed Corporation
78.31-1.48
IRME
IR-Med Inc.
0.03+0.00
LIVN
LivaNova PLC
53.34-0.52
MDT
Medtronic plc.
91.73-1.50
QIPT
Quipt Home Medical Corp.
2.40-0.20
RMD
ResMed Inc.
253.62-2.95
RMSL
RemSleep Holdings, Inc.
0.00+0.00
VVOS
Vivos Therapeutics, Inc.
2.67+0.07